Biotech Companies Urge Congress to Pass Bipartisan ORPHAN Cures Act
February 26, 2024
We are writing to express our strong support for the bipartisan Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act). The legislation, which was introduced by Reps. John Joyce (R-PA) and Wiley Nickel (D-NC) in September,1 corrects a significant flaw in the Inflation Reduction Act (IRA) concerning medicines for rare diseases. Senators Tom Carper (D- DE) and John Barrasso, M.D., (R-WY) introduced the Senate companion to the legislation.
Download Full Comments Below
Biotech Companies Urge Congress to Pass Bipartisan ORPHAN Cures Act
BIO submits comments on the MDH’s proposed regulations regarding Drugs of Substantial Public Interest: Draft Methodology for Public Comment as required in statute by the Prescription Drug Price Transparency Act.
The Biotechnology Innovation Organization appreciates the opportunity to comment on the Center for Medicare and Medicaid Services’ Information Collection Request on the Part C and Part D Medicare Prescription Payment Plan Model Documents.
We are writing to express our strong support for the bipartisan Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act). The legislation, which was introduced by Reps. John Joyce (R-PA) and Wiley Nickel (D-NC) in September,1 corrects a significant flaw in the Inflation Reduction Act (IRA) concerning medicines for rare diseases. Senators Tom Carper (D- DE) and John Barrasso, M.D., (R-WY) introduced the Senate companion to the legislation.